NCT02594189View on ClinicalTrials.gov

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Interventions
OTHER

Live recombinantly derived A/Bethesda/MM1/H3N2 virus

The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02594189 - Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter